Objective:

To discuss the limitations of current pre-eclampsia testing and the potential of PlGF testing to improve care.

Approach:

• Current Standard of Care: The standard relies on clinical signs like elevated blood pressure and proteinuria, which indicate disease progression.
• PlGF Testing Benefits: PlGF testing provides early biological signals of placental health, allowing for better risk stratification and decision-making.
• NICE Recommendations: NICE recommended PlGF testing for suspected pre-eclampsia in 2016, updated in 2022, showing a commitment to evidence-based care.
• Implementation Challenges: Adoption of PlGF testing varies regionally, with barriers related to operational integration, awareness, and clinical inertia.
• Future Directions: Health systems should integrate PlGF testing into triage protocols and invest in training to improve consistency and equity in care.

Key Findings:

• Pre-eclampsia affects 1 in 25 pregnancies in the UK and is a leading cause of maternal and perinatal mortality.
• Current testing methods often fail to identify at-risk patients early.
• PlGF testing can reduce time to diagnosis and improve clinical decision-making.
• There are significant regional variations in the implementation of PlGF testing despite NICE recommendations.

Interpretation:

Limitations:

• Operational and cultural barriers hinder the integration of PlGF testing into clinical workflows.
• There is a need for increased awareness and training among healthcare providers.

Conclusion:

Sources:

• NICE Guidelines